Longhaulers and other trials might cause CytoDyn to issue a "small" PR.
Could NP perhaps also mention the number of OLE and eIND patients enrolled since CD-12 end, and maybe in the last week?
Or would that be too presumptuous for the FDA?
(2)
(0)
CytoDyn Inc (CYDY) Stock Research Links
-
-
-
-
-
-
-